Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Keros Therapeutics in a research report issued on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($4.62) for the year, up from their prior forecast of ($5.12). HC Wainwright currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2026 earnings at ($1.49) EPS, FY2027 earnings at ($6.39) EPS, FY2028 earnings at ($5.72) EPS, FY2029 earnings at ($3.40) EPS and FY2030 earnings at ($0.96) EPS.
Several other analysts have also recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Tuesday. Weiss Ratings lowered shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Leerink Partners decreased their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Hold” and a consensus price target of $20.50.
Keros Therapeutics Trading Down 2.5%
Keros Therapeutics stock opened at $9.99 on Thursday. The company has a 50-day moving average price of $10.64 and a 200 day moving average price of $12.46. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55. The stock has a market cap of $197.72 million, a P/E ratio of -2.70 and a beta of 0.99.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%.
Insider Activity
In related news, Director Julius Knowles sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director owned 10,958 shares of the company’s stock, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at $104,702.24. This trade represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,425 shares of company stock valued at $89,994. Company insiders own 12.60% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC boosted its position in shares of Keros Therapeutics by 416.2% during the first quarter. ADAR1 Capital Management LLC now owns 97,318 shares of the company’s stock worth $1,074,000 after buying an additional 78,467 shares during the period. Empowered Funds LLC raised its holdings in shares of Keros Therapeutics by 142.2% in the 1st quarter. Empowered Funds LLC now owns 145,517 shares of the company’s stock valued at $1,607,000 after buying an additional 85,439 shares during the period. Quantinno Capital Management LP raised its holdings in shares of Keros Therapeutics by 12.5% in the 1st quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock valued at $262,000 after buying an additional 2,639 shares during the period. Lazard Asset Management LLC acquired a new position in Keros Therapeutics during the 1st quarter worth about $129,000. Finally, Globeflex Capital L P acquired a new position in Keros Therapeutics during the 1st quarter worth about $418,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.
About Keros Therapeutics
Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.
Read More
- Five stocks we like better than Keros Therapeutics
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
